ANUH PHARMA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 242.6 INR | +0.71% |
|
+3.99% | +65.52% |
| Apr. 08 | Anuh Pharma Limited Approves Final Dividend for the Financial Year Ended 2022-2023 | CI |
| Apr. 04 | Anuh Pharma Limited Appoints Manan Jayesh Vadhan as Company Secretary and Compliance Officer | CI |
| Sales 2022 | 4.87B 58.28M | Sales 2023 | 5.27B 63.17M | Capitalization | 3.99B 47.78M |
|---|---|---|---|---|---|
| Net income 2022 | 306M 3.66M | Net income 2023 | 362M 4.34M | EV / Sales 2022 | 0.84 x |
| Net cash position 2022 | 210M 2.52M | Net cash position 2023 | 522M 6.25M | EV / Sales 2023 | 0.66 x |
| P/E ratio 2022 |
14.1
x | P/E ratio 2023 |
11
x | Employees | 159 |
| Yield 2022 |
2.04% | Yield 2023 |
2.51% | Free-Float | 30.08% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.06% | ||
| 1 week | +4.35% | ||
| Current month | -0.86% | ||
| 1 month | +12.86% | ||
| 3 months | +48.61% | ||
| 6 months | +87.09% | ||
| Current year | +66.10% |
1 week
215.30
256.60
1 month
212.70265.00
Current year
155.00265.00
1 year
86.00265.00
3 years
77.00265.00
5 years
48.70265.00
10 years
24.50265.00
| Managers | Title | Age | Since |
|---|---|---|---|
Vivek Bipin Shah
CEO | Chief Executive Officer | 38 | 17-03-31 |
| Chief Executive Officer | 43 | - | |
| Director of Finance/CFO | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 66 | 08-10-23 | |
| Director/Board Member | - | 49-03-06 | |
| Director/Board Member | 78 | 80-10-28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 242.6 | +0.71% | 55 007 |
| 24-04-18 | 241 | +0.35% | 73,914 |
| 24-04-16 | 240.1 | +6.83% | 82,744 |
| 24-04-15 | 224.8 | -3.69% | 96,408 |
| 24-04-12 | 233.4 | -0.04% | 64,372 |
Delayed Quote Bombay S.E., April 19, 2024 at 05:58 am EDT
More quotes
Anuh Pharma Limited is an India-based bulk drug manufacturing company. The Company is engaged in the business of manufacturing active pharmaceutical ingredients (API). The Company manufactures Macrolides, Anti-TB, Anti-Bacterials, Anti-Malarial, Anti-Hypertension, Expectorant and Corticosteroids products. Its Macrolides products include Erythromycin, Erythromycin Ethyl Succinate, Erythromycin Stearate, Erythromycin Estolate, Erythromycin Propionate, Erythromycin Phosphate, Erythromycin 11,12 Carbonate and Azithromycin. Its Anti-TB products include Pyrazinamide and Isoniazid. Its Anti-Malarial products include Sulfadoxine and Pyrimethamine. Anti-Bacterials products include Chloramphenicol and Chloramphenicol Palmitate. Anti-Hypertension products include Losartan Potassium, Telmisartan and Atorvastatin Calcium. Its Expectorant product includes Ambroxol Hydrochloride. Its Quinolones product includes Moxifloxacin Hydrochloride.
Sector
Pharmaceuticals
Calendar
2024-05-29
- Q4 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| +66.10% | 144M | |
| +21.03% | 43.54B | |
| +16.96% | 21.74B | |
| +8.05% | 13.02B | |
| +4.77% | 13.53B | |
| +34.13% | 11.28B | |
| -11.05% | 6.99B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +7.71% | 5.09B |
- Stock Market
- Equities
- ANUHPHR6 Stock
